Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Thoracic 3Gastrointestinal 2Breast 2Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 50Nivolumab 21Docetaxel 11atezolizumab 7Ipilimumab 7avelumab 6Cyclophosphamide 6Paclitaxel 5Cetuximab 5Carboplatin 5fludarabine 4Radiotherapy 4Gemcitabine 4utomilumab 3spartalizumab 3lenvatinib 3durvalumab 3Trastuzumab 3Specimen Handling 3Interleukin-2 3Cisplatin 3Bevacizumab 3Albumin-Bound Paclitaxel 3zimberelimab 2tremelimumab 2tisotumab vedotin 2tislelizumab 2sargramostim 2obinutuzumab 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × budigalimab × Genitourinary × Clear all
NCT06158958 2025-10-27

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

AbbVie

Phase 1 Terminated
27 enrolled
GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡